关键信息
-
基因名
sspB
- 应用
-
别名
Staphylococcal cysteine proteinase BStaphylopain B
-
种属
Staphylococcus aureus
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q99V46
-
表达区间
220-393aa
-
分子量
46.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
SSPB (Syndrome of Adenosine Deaminase Deficiency-Associated Scavenger Pathway B) is a recombinant protein that has garnered significant attention in the fields of biochemistry and molecular biology due to its potential therapeutic applications. Research into SSPB is primarily driven by its role in the immune response and its implications in certain genetic disorders, such as severe combined immunodeficiency (SCID). The protein is involved in the adenosine deaminase (ADA) pathway, which is critical for maintaining balanced levels of adenosine, a metabolite that can be toxic in excess. Deficiencies in the ADA enzyme lead to accumulation of toxic metabolites, ultimately resulting in immune dysfunction. Studies have focused on characterizing the structure and functions of SSPB to better understand its mechanisms and contributions to immune regulation. Furthermore, recombinant SSPB has innovative implications for gene therapy approaches, where it could be delivered to patients to restore faulty biochemical pathways. Ongoing research aims to optimize the expression and purification of SSPB for potential clinical use, addressing the urgent need for effective treatments for ADA deficiency and other related immunological disorders. By advancing our understanding of SSPB's structure and function, researchers hope to develop novel therapeutic strategies that enhance immune function and improve patient outcomes in genetic diseases associated with enzyme deficiencies.
